DELGADO, Julio, Michael DOUBEK, Tycho BAUMANN, Jana KOTAŠKOVÁ, Stefano MOLICA, Pablo MOZAS, Alfredo RIVAS-DELGADO, Fortunato MORABITO, Šárka POSPÍŠILOVÁ and Emili MONTSERRAT. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. American Journal of Hematology. Hoboken: John Wiley & Sons, 2017, vol. 92, No 4, p. 375-380. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.24660.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI
Authors DELGADO, Julio (724 Spain), Michael DOUBEK (203 Czech Republic, belonging to the institution), Tycho BAUMANN (724 Spain), Jana KOTAŠKOVÁ (203 Czech Republic, belonging to the institution), Stefano MOLICA (380 Italy), Pablo MOZAS (724 Spain), Alfredo RIVAS-DELGADO (724 Spain), Fortunato MORABITO (380 Italy), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Emili MONTSERRAT (724 Spain).
Edition American Journal of Hematology, Hoboken, John Wiley & Sons, 2017, 0361-8609.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.303
RIV identification code RIV/00216224:14740/17:00095652
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1002/ajh.24660
UT WoS 000399299300022
Keywords in English INDEPENDENT PREDICTOR; MULTIVARIATE-ANALYSIS; GENOMIC ABERRATIONS; SURVIVAL ANALYSIS; CD38 EXPRESSION; DOUBLING TIME; 1ST TREATMENT; TRIAL; INDEX; GENE
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 28/2/2018 16:18.
Abstract
Rai and Binet staging systems are important to predict the outcome of patients with chronic lymphocytic leukemia (CLL) but do not reflect the biologic diversity of the disease nor predict response to therapy, which ultimately shape patients' outcome. We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV+no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV+adverse FISH cytogenetics). In 524 unselected subjects with CLL, the 10-year overall survival was 82% (95% CI 76%-88%), 52% (45%-62%), and 27% (17%-42%) for the low-, intermediate-, and high-risk groups, respectively. Patients with low-risk comprised around 50% of the series and had a life expectancy comparable to the general population. The prognostic model was fully validated in two independent cohorts, including 417 patients representative of general CLL population and 337 patients with Binet stage A CLL. The model had a similar discriminatory value as the CLL-IPI. Moreover, it applied to all patients with CLL independently of age, and separated patients with different risk within Rai or Binet clinical stages. The biomarkers-only CLL prognostic system presented here simplifies the CLL-IPI and could be useful in daily practice and to stratify patients in clinical trials.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
NV15-30015A, research and development projectName: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.
NV15-31834A, research and development projectName: Vliv selekce genomických poškození na průběh chronické lymfocytární leukémie
PrintDisplayed: 15/7/2024 02:13